Skip to main content

Market Overview

UPDATE: Oppenheimer Reiterates Perform Rating, Raises PT on DexCom on 4Q12 Revenues


In a report published Friday, Oppenheimer reiterated its Perform rating on DexCom (NASDAQ: DXCM), and slightly raised its price target from $14.00 to $15.00.

Oppenheimer noted, “DexCom's 4Q12 revenues of $33M included $31.7M in product revenues (in line with pre-announcement). Management reiterated 2013 product revenue guidance of $120-130M. The call centered on progress with the launch of the new G4 Platinum and timing of pipeline opportunities. Overall, G4 initial demand appears solid. With G4 expectations already appropriately high and as we monitor the progress of competitors, we rate DXCM shares Perform. Pipeline progress, particularly potential upside from a pediatric claim or improved visibility on a US in-hospital monitor with EW, could make us more constructive at current levels.”

DexCom closed on Thursday at $14.13.

Latest Ratings for DXCM

Apr 2021Canaccord GenuityMaintainsBuy
Apr 2021Raymond JamesMaintainsOutperform
Apr 2021CitigroupMaintainsBuy

View More Analyst Ratings for DXCM
View the Latest Analyst Ratings


Related Articles (DXCM)

View Comments and Join the Discussion!

Posted-In: OppenheimerAnalyst Color Price Target Analyst Ratings

Latest Ratings

PHXSeaport GlobalInitiates Coverage On
AFCGLake StreetInitiates Coverage On29.0
OSSNoble Capital MarketsUpgrades7.0
NCNOGabelli & Co.Upgrades
HAECJS SecuritiesUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at